Immune-mediated thrombotic thrombocytopenic purpura following administration of Pfizer-BioNTech COVID-19 vaccine
Gaetano Giuffrida, Annalisa Condorelli, Mary Ann Di Giorgio, Uroš Markovic, Roberta Sciortino, Daniela Nicolosi, Francesco Di Raimondo
Abstract
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a recently discovered coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease affected well over a hundred million people all over the world and mortality rates were greater in the elderly population. The quick development of safe and effective vaccines represents an important step in the management of the ongoing pandemic and, so far, four vaccines have been approved by the European Medicines Agency, including mRNA (Pfizer-BioNTech and Moderna) and adenovirus-based vaccines (AstraZeneca and Johnson & Johnson).